Freedom from AML evolution for MDS patients classified by clinical and molecular features. Evaluation was performed using (A) clinical features (ie, IPSS categories, P < .001), (B) subgrouping in the unsupervised GEP Figure 1 dendrogram (the 14 distal patients [group 2] vs the remaining 21 MDS patients [group 1]; P = .005), and (C) subgrouping by the overexpression (or not) of genes composing the poor risk gene signature (PRS; P = .01). The Kaplan-Meier curves show significant differences in AML progression using each of these analyses, with significant separation of the IPSS Int-1 subgroup using the poor risk signature (C).